HomeCompareKGTFF vs ABBV

KGTFF vs ABBV: Dividend Comparison 2026

KGTFF yields 10.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KGTFF wins by $436203.70M in total portfolio value
10 years
KGTFF
KGTFF
● Live price
10.00%
Share price
$1.10
Annual div
$0.11
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$436203.80M
Annual income
$427,982,070,990.02
Full KGTFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KGTFF vs ABBV

📍 KGTFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKGTFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KGTFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KGTFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KGTFF
Annual income on $10K today (after 15% tax)
$850.00/yr
After 10yr DRIP, annual income (after tax)
$363,784,760,341.52/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, KGTFF beats the other by $363,784,739,285.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KGTFF + ABBV for your $10,000?

KGTFF: 50%ABBV: 50%
100% ABBV50/50100% KGTFF
Portfolio after 10yr
$218101.95M
Annual income
$213,991,047,880.89/yr
Blended yield
98.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KGTFF
No analyst data
Altman Z
0.4
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KGTFF buys
0
ABBV buys
0
No recent congressional trades found for KGTFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKGTFFABBV
Forward yield10.00%3.06%
Annual dividend / share$0.11$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$436203.80M$102.3K
Annual income after 10y$427,982,070,990.02$24,771.77
Total dividends collected$435647.34M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KGTFF vs ABBV ($10,000, DRIP)

YearKGTFF PortfolioKGTFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,700$2,000.00$11,550$430.00+$1.1KKGTFF
2$18,337$4,747.66$13,472$627.96+$4.9KKGTFF
3$32,433$12,812.76$15,906$926.08+$16.5KKGTFF
4$77,063$42,359.97$19,071$1,382.55+$58.0KKGTFF
5$270,590$188,131.85$23,302$2,095.81+$247.3KKGTFF
6$1,524,261$1,234,730.29$29,150$3,237.93+$1.50MKGTFF
7$14,631,657$13,000,698.03$37,536$5,121.41+$14.59MKGTFF
8$248,919,512$233,263,638.51$50,079$8,338.38+$248.87MKGTFF
9$7,683,863,097$7,417,519,219.51$69,753$14,065.80+$7683.79MKGTFF
10$436,203,804,504$427,982,070,990.02$102,337$24,771.77+$436203.70MKGTFF

KGTFF vs ABBV: Complete Analysis 2026

KGTFFStock

Krung Thai Bank Public Company Limited provides various commercial banking products and services. The company operates through three segments: Retail Banking, Wholesale Banking, and Treasury and Investment. It provides various retail banking products and services, including current, savings, and fixed deposit accounts; time and foreign currency deposits; personal and housing loans; debit, travel, cash and top up, and credit cards; investment services; travel, motor, and home asset insurance products; money transfer, payment and top up, foreign exchange, and overseas education services; and e-banking services. The company also offers SME loans for small and medium businesses; and international business loans. In addition, it provides corporate banking products and services comprising cash management services, such as collection, liquidity management, and transfer and payment services; fixed deposit and current accounts; foreign currency and term deposits; cards; Fx, interest rate, equity, commodity, and credit derivatives; financial advisory services related to merger and acquisition transactions; financial advisory, underwriting, and selling agent services for products offered through the equity capital markets; project finance advisory and feasibility study services, as well as e-banking services; and investment solutions, such as government and corporate bonds, structured notes, and investment units. The company provides its services through a network of branches in Thailand and various centers internationally. Krung Thai Bank Public Company Limited was founded in 1966 and is headquartered in Bangkok, Thailand.

Full KGTFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KGTFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KGTFF vs SCHDKGTFF vs JEPIKGTFF vs OKGTFF vs KOKGTFF vs MAINKGTFF vs JNJKGTFF vs MRKKGTFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.